by Plus Therapeutics | Jun 16, 2025 | GBM
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle...
by Plus Therapeutics | Jun 10, 2025 | GBM
Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial As part of our ongoing commitment to highlight the incredible medical professionals behind the ReSPECT-GBM clinical trial, today we are proud to...
by Plus Therapeutics | Jun 8, 2025 | GBM
Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation Today is Brain Tumor Awareness Day—a day dedicated to raising awareness for those affected by brain tumors and honoring the patients, caregivers, and advocates working...
by Plus Therapeutics | Jun 4, 2025 | GBM
New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner A new article by Ariana Pelosci at Cancer Network highlights promising data from Plus Therapeutics’ ongoing Phase 1/2 ReSPECT-GBM clinical trial, which is...
by Plus Therapeutics | May 27, 2025 | GBM
Honoring National Gray Day: Advancing Brain Cancer Awareness and Research Today marks National Gray Day, a powerful observance during Brain Cancer Awareness Month dedicated to honoring the lives lost to brain cancer and standing in solidarity with patients, survivors,...
by Plus Therapeutics | May 1, 2025 | GBM, LM, PBC, Uncategorized
Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...
Recent Comments